Skip Navigation
Print This Page
Share this page: More

Search Results

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma.
Protocol Number:
Phase II
Julie Brahmer
Primary objective is to compare the overall survival between the 2 treatment arms (Tremelimumab and placebo) in subjects with unresectable malignant mesothelioma. The safety, tolerability, immunogenicity and pharmacokinetics of Tremelimumab will be evaluated. Biomarkers and their association with Tremlimumab treatment and clinical outcome will be examined.
Adult subjects with histologically and/or cytologically confirmed unresectable pleural or peritoneal malignant mesothelioma . Received no more than 2 prior systemic chemotherapy regimens for advanced disease including first-line Pemetrexed combination with a platinum agent. ECOG PS 0-1. Adequate renal, hepatic and bone marrow function. Brain metastases allowed if treated and stable. No inflammatory bowel disease, diarrhea, immunosuppressive medications or disease.
Patients will be randomized to receive either Tremelimumab or placebo IV every 4 weeks for six doses (week 25). Treatment will then be every 12 weeks until disease progression, unacceptable toxicity, or other reason to discontinue treatment.
Last Update
09/20/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer